Grace Therapeutics, Inc.

Grace Therapeutics is a late-stage biopharmaceutical company that develops novel treatments for rare and orphan diseases. Their clinical assets have been awarded Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States. They have additional intellectual property protection with over 40 granted and pending patents.